Cardiac allograft vasculopathy prevention: Difference between revisions

Jump to navigation Jump to search
Line 20: Line 20:


* Associated with significantly reduced incidence of [[graft rejection]].
* Associated with significantly reduced incidence of [[graft rejection]].
* Serial [[IVUS]] studies to evaluate intimal proliferation demonstrated smaller increase in maximal intimal thickness and intimal index in patients taking [[everolimus]]. Similar results were found in trials that studied [[sirolimus]].  
* Serial [[IVUS]] studies to evaluate intimal proliferation demonstrated smaller increase in maximal intimal thickness and intimal index in patients taking [[everolimus]] <ref name="pmid12944570">{{cite journal| author=Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA et al.| title=Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. | journal=N Engl J Med | year= 2003 | volume= 349 | issue= 9 | pages= 847-58 | pmid=12944570 | doi=10.1056/NEJMoa022171 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12944570  }} </ref>. Similar results were found in trials that studied [[sirolimus]] <ref name="pmid23856215">{{cite journal| author=Matsuo Y, Cassar A, Yoshino S, Flammer AJ, Li J, Gulati R et al.| title=Attenuation of cardiac allograft vasculopathy by sirolimus: Relationship to time interval after heart transplantation. | journal=J Heart Lung Transplant | year= 2013 | volume= 32 | issue= 8 | pages= 784-91 | pmid=23856215 | doi=10.1016/j.healun.2013.05.015 | pmc=PMC3727915 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23856215  }} </ref>.  
* Side effect profile:
* Side effect profile:
** Everolimus: increase in [[serum creatinine]] levels, [[hyperlipidemia]], [[anemia]], [[thrombocytopenia]], [[peripheral edema]], [[hypertension]]. However, opportunistic viral infections less often seen.
** Everolimus: increase in [[serum creatinine]] levels, [[hyperlipidemia]], [[anemia]], [[thrombocytopenia]], [[peripheral edema]], [[hypertension]]. However, opportunistic viral infections less often seen.

Revision as of 22:52, 11 October 2014

Cardiac allograft vasculopathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Differentiating Cardiac allograft vasculopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Coronary Angiography

Intravascular Ultrasound

Optical Coherence Tomography

CT

MRI

Echocardiography

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cardiac allograft vasculopathy prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cardiac allograft vasculopathy prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cardiac allograft vasculopathy prevention

CDC on Cardiac allograft vasculopathy prevention

Cardiac allograft vasculopathy prevention in the news

Blogs on Cardiac allograft vasculopathy prevention

Directions to Hospitals Treating Cardiac allograft vasculopathy

Risk calculators and risk factors for Cardiac allograft vasculopathy prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2] Raviteja Guddeti, M.B.B.S. [3]

Overview

Prevention

As the pathogenesis of CAV consists of both immunological and non-immunological insults, it has been suggested that preventative strategies should consist of control of risk factors for CAV and optimal immunosuppressive therapy. However, the best preventative strategy to delay development of CAV is yet to be determined.

Optimization of Immunosuppressive Therapy

Options for immunosuppressive therapy for prevention of CAV include [1]:

Everolimus and Sirolimus

  • Act by inhibiting mTOR (mammalian target), thereby having anti-proliferative effects in response to allo-antigens.
  • Everolimus is currently not FDA approved for clinical use in the United States.
  • Associated with significantly reduced incidence of graft rejection.
  • Serial IVUS studies to evaluate intimal proliferation demonstrated smaller increase in maximal intimal thickness and intimal index in patients taking everolimus [2]. Similar results were found in trials that studied sirolimus [3].
  • Side effect profile:

Mycophenolate mofetil

  • Studies have shown trend towards a lower maximal intimal thickness on IVUS, lower incidence of retransplantation and death with mycophenolate when compared to azathioprine.

Calcineurin inhibitors

References

  1. Mehra MR (2006). "Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy". Am J Transplant. 6 (6): 1248–56. doi:10.1111/j.1600-6143.2006.01314.x. PMID 16686747.
  2. Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA; et al. (2003). "Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients". N Engl J Med. 349 (9): 847–58. doi:10.1056/NEJMoa022171. PMID 12944570.
  3. Matsuo Y, Cassar A, Yoshino S, Flammer AJ, Li J, Gulati R; et al. (2013). "Attenuation of cardiac allograft vasculopathy by sirolimus: Relationship to time interval after heart transplantation". J Heart Lung Transplant. 32 (8): 784–91. doi:10.1016/j.healun.2013.05.015. PMC 3727915. PMID 23856215.

Template:WH Template:WS